The global Duchenne muscular dystrophy treatment market is estimated to be valued at US$ 2 billion in 2024 and is expected to exhibit a CAGR of 47% over the forecast period 2024-2028.Key TakeawaysKey players operating in the Duchenne muscular dystrophy treatment are Sarepta Therapeutics, Pfizer, PTC Therapeutics, Summit Therapeutics, and others. Sarepta Therapeutics' Exondys 51 was the first...
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian